Results 271 to 280 of about 2,636,203 (317)

A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction

open access: yesESC Heart Failure, EarlyView.
The QUAD score was developed to promote adherence to clinical practice guidelines for patients with heart failure and a reduced left ventricular ejection fraction <50%. In newly diagnosed patients who had completed therapy titration, we found that patients with an excellent QUAD score had a significant reduction in the risk of mortality or ...
Henry Oluwasefunmi Savage   +23 more
wiley   +1 more source

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı   +4 more
wiley   +1 more source

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

open access: yesESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra   +25 more
wiley   +1 more source

Angiotensin receptor-neprilysin inhibition and combination use of guideline-directed medical therapies in acute heart failure. [PDF]

open access: yesEur J Heart Fail
Tanaka A   +5 more
europepmc   +1 more source

Pathogenic glycosyltransferase genes and potential therapeutic drugs in pressure overload‐induced heart failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Protein glycosylation regulated by glycosyltransferases is an important type of post‐translational modification. The role of the glycosyltransferase genes (GTGs) in heart failure (HF) remains unclear and requires further investigation.
Jiahe Wu   +5 more
wiley   +1 more source

Re‐PERFUSE: Phase 1b study of AZD3427, a novel relaxin receptor agonist, on renal perfusion in HFrEF patients

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Renal impairment frequently coexists with heart failure (HF) and is associated with increased risk of poor clinical outcomes. This highlights the urgent need for therapies targeting both cardiac and renal dysfunction. AZD3427, a long‐acting recombinant fusion protein and relaxin analogue that selectively activates the relaxin family ...
Marcin Ufnal   +9 more
wiley   +1 more source

Angiotensin Receptor Blockers for Hypertension and Risk of Epilepsy.

open access: yesJAMA Neurol
Wen X   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy